

Ovoca Bio Public Limited Company

Interim Unaudited Consolidated Financial Statements
for the six months ended 30 June 2024

Ovoca Bio plc
Interim results for the six months ended 30 June 2024

CONDENSED CONSOLIDATED INCOME STATEMENT

	Unaudited 6 Months ended 30/06/2024 €'000	Unaudited 6 Months ended 30/06/2023 €'000	Unaudited 6 Months ended 30/06/2024 \$'000	Unaudited 6 Months ended 30/06/2023 \$'000
Continuing Operations				
Administration expenses	(319)	(1,022)	(342)	(1,106)
Other losses	(922)	(1,334)	(991)	(1,446)
Operating loss	(1,241)	(2,356)	(1,333)	(2,552)
Finance costs	(3)	(18)	(3)	(20)
Finance income	0	1	0	1
Loss for the period before tax	(1,244)	(2,373)	(1,336)	(2,571)
Income tax	-	-	-	-
Loss for the period from continuing operations	(1,244)	(2,373)	(1,336)	(2,571)
Discontinued operations	-	-	-	-
Loss from discontinued operations net of tax	-	-	-	-
Loss for the period	(1,244)	(2,373)	(1,336)	(2,571)
Loss for the period attributable to:				
Owners of the parent	(1,244)	(2,373)	(1,336)	(2,571)
	(1,244)	(2,373)	(1,336)	(2,571)
Loss per share				
Basic loss per share from continuing operations	(1.34)	(2.91)	(1.44)	(3.15)
Basic loss per share from discontinued operations	-	-	-	-
Fully diluted loss per share from continuing operations	(1.34)	(2.91)	(1.44)	(3.15)
Fully diluted loss per share from discontinued operations	-	-	-	-

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE (LOSS)/INCOME

	Unaudited 6 Months ended 30/06/2024 €'000	Unaudited 6 Months ended 30/06/2023 €'000	Unaudited 6 Months ended 30/06/2024 \$'000	Unaudited 6 Months ended 30/06/2023 \$'000
Loss for the period	(1,244)	(2,373)	(1,336)	(2,571)
Other comprehensive income/(expense):				
<i>Items that may not be reclassified subsequently to profit or loss</i>				
Fair value movement on equity securities designated as at FVOCI	-	-	-	-
Exchange movement on equity securities designated as at FVOCI	-	-	-	-
<i>Items that may be reclassified subsequently to profit or loss</i>				
Foreign exchange gain/(loss) arising from translation of financial statements of a foreign operation	982	(206)	(4,466)	(127)
Total comprehensive loss for the period	(262)	(2,579)	(5,802)	(2,698)
Total comprehensive loss for the period attributable to:				
Owners of the parent	(262)	(2,579)	(5,802)	(2,698)
	(262)	(2,579)	(5,802)	(2,698)

There is no income tax impact in respect of components recognised within the consolidated statement of comprehensive income.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

	Share capital €'000	Treasury Shares €'000	Share based payment reserve €'000	Other reserves €'000	Foreign Currency translation reserve €'000	Retained earnings €'000	Total (attributable to owners of the parent) €'000
Unaudited							
At 1 January 2024	11,057	(547)	46	1,288	5,093	(14,436)	2,501
Comprehensive loss							
Loss for the period	-	-	-	-	-	(1,244)	(1,244)
Other comprehensive loss							
Foreign exchange gain arising from translation of financial statements of a foreign operation	-	-	-	-	982	-	982
Total comprehensive loss for the period	-	-	-	-	982	(1,244)	(262)
Balance at 30 June 2024	11,057	(547)	46	1,288	6,075	(15,680)	2,239
Unaudited							
At 1 January 2023	11,057	(547)	46	1,288	5,525	(9,734)	7,635
Comprehensive loss							
Loss for the period	-	-	-	-	-	(2,373)	(2,373)
Other comprehensive loss							
Movement on equity securities designated as at FVOCI	-	-	-	-	-	-	-
Exchange movement on equity securities designated as at FVOCI	-	-	-	-	-	-	-
Foreign exchange gain arising from translation of financial statements of a foreign operation	-	-	-	-	(206)	-	(206)
Total comprehensive (loss)/income for the period	-	-	-	-	(206)	(2,373)	(2,578)
Balance at 30 June 2023	11,057	(547)	46	1,288	5,320	(12,107)	5,057

Ovoca Bio plc
as at 30 June 2024

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Unaudited 30/06/2024 €'000	Audited 31/12/2023 €'000	Unaudited 30/06/2024 \$'000	Audited 31/12/2023 \$'000
Assets				
Current assets				
Trade and other receivables	175	121	188	134
Cash and cash equivalents	2,925	3,337	3,133	3,683
	3,100	3,458	3,321	3,817
Assets held for sale	1	10	1	11.00
Total assets	3,101	3,468	3,322	3,828
Equity and liabilities				
Equity				
Ordinary shares	11,057	11,057	15,586	15,586
Treasury shares	(547)	(547)	(607)	(607)
Other reserves	1,288	1,288	1,774	1,774
Foreign currency translation reserve	6,075	5,093	(3,834)	279
Share based payment reserve	46	46	52	52
Retained earnings	(15,680)	(14,436)	(10,573)	(14,322)
	2,239	2,501	2,398	2,762
Non controlling interest	-	-	-	-
	2,239	2,501	2,398	2,762
Current liabilities				
Trade and other payables	451	369	483	407
Provisions	1	159	1	175
	452	528	484	582
Liabilities included in the disposal group classified as held for sale	411	439	440	484
Total equity and liabilities	3,101	3,468	3,321	3,828

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

	Unaudited 30/06/2024 €'000	Unaudited 30/06/2023 €'000	Unaudited 30/06/2024 \$'000	Unaudited 30/06/2023 \$'000
Cash flows from operating activities				
Loss for the period before tax	(1,244)	(2,373)	(1,336)	(2,571)
Depreciation and amortisation	-	121	-	131
Finance income	3	-	3	-
Decrease/(increase) in inventories	-	17	-	18
Decrease/(increase) in trade and other receivables	(45)	1,023	(44)	1,087
(Decrease)/increase in trade and other payables	(134)	(913)	(142)	(963)
Net decrease in assets & liabilities included in the disposal group	29	(37)	31	(36)
Goodwill impairment	-	1,482	-	1,875
Net cash used in operating activities	(1,391)	(680)	(1,487)	(758)
Cash flow from financing activities				
Finance costs	(3)	(17)	(3)	(19)
Net cash generated from financing activities	(3)	(17)	(3)	(19)
Cash flows from investing activities				
Additions of research and development costs internally developed	-	-	-	-
Revaluation of Intangible assets	-	4	-	-
Additions to property, plant and equipment	-	-	-	-
Net cash generated from investing activities	0	4	0	0
Effects of foreign exchange	982	(211)	940	(127)
Net decrease in cash and cash equivalents	(412)	(903)	(550)	(904)
Cash and cash equivalents at the beginning of period	3,337	3,703	3,683	3,953
Cash and cash equivalents at the end of the period	2,925	2,800	3,133	3,049
Cash and Cash equivalents included in the disposal group	-	-	-	-
Cash and Cash Equivalents for Continuing operations	2,925	2,800	3,133	3,049

Ovoca Bio plc
Interim results for the six months ended 30 June 2024

1 Basis of Preparation

The interim consolidated financial statements for the six months ended 30 June 2024 are presented in € '000, which is the functional currency of the Group. The US\$ '000 are shown for information purposes only. The Financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board as adopted by European Union.

The interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual financial statements for the financial year ended 31 December 2023.

2 Accounting Policies

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the Group's annual financial statements for the financial year ended 31 December 2023.

Other pronouncements

Some accounting pronouncements which have become effective from 1 January 2024 and have therefore been adopted do not have a significant impact on the Group's financial results or position.

3 Going concern

As announced in the last Annual Report, Management had decided not to pursue immediate development plans for Orenetide as future economic benefits to the Company remain unclear. The Board continues to explore the development of alternative businesses including, but not limited to the search for assets or other companies for licensing and/or sale of business or M&A transactions (including a form of business restructuring with potentially synergetic companies). Management had considered the existing potential of the Company in its current state to realise value for its shareholders and is researching potential strategic opportunities that fit with the skillset and competences of the Company's management. A number of options are under consideration and reviews and discussions are ongoing.

4 Estimates

When preparing the Interim Financial Statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from judgements, estimates and assumptions made by management, and will seldom equal the estimated results. The judgements, estimates and assumptions applied in the Interim Financial Statements, including the key sources of estimation uncertainty, were the same as those applied in the Group's last annual Financial Statements for the financial year ended 31 December 2023.

5 Segmental reporting

Information regarding the Group's operating segments is set out below in accordance with IFRS 8 Operating Segments. IFRS 8 requires operating segments to be identified on the basis of internal reports that are regularly reviewed by the Group's chief operating decision maker and used to allocate resources to the segments and to assess their performance.

At 30 June 2024 and 31 December 2023, the Group had three business segments, Bio-pharmaceutical, Investing and Administrative. Bio-pharmaceutical activities are exclusively carried out in Australia. Investing activities are carried out by another subsidiary, Silver Star Ltd., a company located in Bermuda. Administrative costs represent group administration costs, incurred in primarily in Ireland.

The Exploration segment and some operations in the Biopharmaceutical segment are presented as being discontinued as reported in the 31 December 2023 Annual Report.

Continuing Operations

Period ended 30 June 2024	Bio-pharmaceutical	Investment	Administrative	Total
	€'000	€'000	€'000	€'000
Depreciation & amortisation	-	-	-	-
Administration expenses	(24)	(255)	(46)	(325)
Other gains/(losses)	-	(423)	(342)	(765)
Operating loss	(24)	(678)	(388)	(1,090)
Finance costs	-	(1)	(2)	(3)
Finance income	-	-	-	-
Loss before tax	(24)	(679)	(390)	(1,092)
Income Tax	-	-	-	-
Loss after tax	(24)	(679)	(390)	(1,092)
Segment assets	1,143	2,588	(631)	3,101
Segment liabilities	(19)	(430)	(3)	(452)
Net assets	1,124	2,158	(634)	2,649

Period ended 30 June 2023	Bio-pharmaceutical	Investment	Administrative	Total
	€'000	€'000	€'000	€'000
Depreciation & amortisation	-	-	-	-
Administration expenses	(611)	(100)	(311)	(1,022)
Other gains/(losses)	(751)	76	(660)	(1,335)
Operating loss	(1,362)	(24)	(971)	(2,357)
Finance costs	(15)	-	(2)	(17)
Finance income	-	-	-	-
Loss before tax	(1,377)	(24)	(973)	(2,373)
Income Tax	-	-	-	-
Loss after tax	(1,377)	(24)	(973)	(2,373)
Segment assets	3,117	1,937	822	5,877
Segment liabilities	(245)	(187)	(408)	(820)
Net assets	2,872	1,770	414	5,057

6 Financial Instruments

The Group monitors relevant aspects of financial instrument risk on an ongoing basis. Financial instrument risks primarily relates to foreign exchange risk, credit risk, liquidity risk and market risk as reported in the 31 December 2023 annual report.

	Unaudited	Audited	Unaudited	Audited
	30/06/2024	31/12/2023	30/06/2024	31/12/2023
	€'000	€'000	US\$'000	US\$'000
Financial assets not measured at fair value				
Cash and cash equivalents	2,925	3,337	3,133	3,683
Other debtors	176	131	189	146
	3,101	3,468	3,322	3,829
Financial assets measured at fair value				
Equity securities designated at FVOCI	0	0	0	0
	0	0	0	0
Financial liabilities not measured at fair value				
Trade and other payables	863	967	924	1066
	863	967	924	1066

The carrying amount of the financial assets and liabilities is considered a reasonable approximation of fair value:

- Other debtors
- Cash and cash equivalents
- Trade and other payables.

7 Dividends

The company made no distributions during the period.

8 Events after the reporting period

There are no events after the reporting period that require to be reported.

9 Approval of the financial statements

The interim report was approved by the Board of Directors on 25 Sept 2024 and is included on the Company's website, www.ovocabio.com.